Enzalutamide and ruxolitinib

Susan Hobson, James Waddell, Dominic Solimando

Research output: Contribution to journalReview article

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Original languageEnglish (US)
Pages (from-to)104-107
Number of pages4
JournalHospital Pharmacy
Volume48
Issue number2
DOIs
StatePublished - Feb 1 2013

Fingerprint

Oncology
Postal Service
Pharmacists
Pharmaceutical Services
Chemotherapy
Poisons
Highway systems
Antineoplastic Agents
Drug Therapy
Neoplasms
INCB018424
MDV 3100
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Pharmacy

Cite this

Enzalutamide and ruxolitinib. / Hobson, Susan; Waddell, James; Solimando, Dominic.

In: Hospital Pharmacy, Vol. 48, No. 2, 01.02.2013, p. 104-107.

Research output: Contribution to journalReview article

Hobson, S, Waddell, J & Solimando, D 2013, 'Enzalutamide and ruxolitinib', Hospital Pharmacy, vol. 48, no. 2, pp. 104-107. https://doi.org/10.1310/hpj4802-104
Hobson, Susan ; Waddell, James ; Solimando, Dominic. / Enzalutamide and ruxolitinib. In: Hospital Pharmacy. 2013 ; Vol. 48, No. 2. pp. 104-107.
@article{a752c6dc35364078a938190cdb073a70,
title = "Enzalutamide and ruxolitinib",
abstract = "The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.",
author = "Susan Hobson and James Waddell and Dominic Solimando",
year = "2013",
month = "2",
day = "1",
doi = "10.1310/hpj4802-104",
language = "English (US)",
volume = "48",
pages = "104--107",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "2",

}

TY - JOUR

T1 - Enzalutamide and ruxolitinib

AU - Hobson, Susan

AU - Waddell, James

AU - Solimando, Dominic

PY - 2013/2/1

Y1 - 2013/2/1

N2 - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

AB - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

UR - http://www.scopus.com/inward/record.url?scp=84873464569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873464569&partnerID=8YFLogxK

U2 - 10.1310/hpj4802-104

DO - 10.1310/hpj4802-104

M3 - Review article

VL - 48

SP - 104

EP - 107

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 2

ER -